Literature DB >> 18396246

Behavioral changes with paranoia in an elderly woman taking atorvastatin.

Jessica T Peters1, Candice L Garwood, Marybeth Lepczyk.   

Abstract

BACKGROUND: There have been a number of published reports of central nervous system (CNS) adverse effects with statins. CASE
SUMMARY: A 79-year-old woman developed paranoia, anxiety, and behavioral changes approximately 2.5 weeks after starting atorvastatin 10 mg/d. The patient had no other medication changes at this time. After 2 months of therapy, the patient discontinued atorvastatin, and her symptoms fully resolved after 4 days.
CONCLUSIONS: This is the first case report, to our knowledge, describing paranoia as one of the symptoms associated with statin therapy. Our report suggests an adverse reaction due to the initiation of atorvastatin via the temporal relationship between the start of atorvastatin and symptom onset, as well as termination of therapy and subsequent symptom disappearance. Use of the Naranjo adverse drug reaction probability scale to assess causality revealed a "probable" association (score, 5) for this adverse event. This report emphasizes the possibility of paranoia as a CNS adverse effect due to statin therapy. Statins are frequently used in older populations and should therefore be considered when such CNS adverse effects occur during therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18396246     DOI: 10.1016/j.amjopharm.2008.03.001

Source DB:  PubMed          Journal:  Am J Geriatr Pharmacother        ISSN: 1876-7761


  7 in total

Review 1.  Cognitive effects of statin medications.

Authors:  Brendan J Kelley; Stephen Glasser
Journal:  CNS Drugs       Date:  2014-05       Impact factor: 5.749

2.  Psychologic disorders and statin use: a propensity score-matched analysis.

Authors:  Ishak Mansi; Christopher R Frei; Mary J Pugh; Eric M Mortensen
Journal:  Pharmacotherapy       Date:  2013-04-26       Impact factor: 4.705

3.  The association of statin use and statin type and cognitive performance: analysis of the reasons for geographic and racial differences in stroke (REGARDS) study.

Authors:  Stephen P Glasser; Virginia Wadley; Suzanne Judd; Bhumika Kana; Valerie Prince; Nancy Jenny; Brett Kissela; Monika Safford; Ronald Prineas; George Howard
Journal:  Clin Cardiol       Date:  2010-05       Impact factor: 2.882

Review 4.  Neuropsychiatric adverse events associated with statins: epidemiology, pathophysiology, prevention and management.

Authors:  Marco Tuccori; Sabrina Montagnani; Stefania Mantarro; Alice Capogrosso-Sansone; Elisa Ruggiero; Alessandra Saporiti; Luca Antonioli; Matteo Fornai; Corrado Blandizzi
Journal:  CNS Drugs       Date:  2014-03       Impact factor: 5.749

Review 5.  Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism.

Authors:  Beatrice A Golomb; Marcella A Evans
Journal:  Am J Cardiovasc Drugs       Date:  2008       Impact factor: 3.571

6.  Statin-associated psychiatric adverse events: a case/non-case evaluation of an Italian database of spontaneous adverse drug reaction reporting.

Authors:  Marco Tuccori; Francesco Lapi; Arianna Testi; Daniela Coli; Ugo Moretti; Alfredo Vannacci; Domenico Motola; Francesco Salvo; Alma Lisa Rivolta; Corrado Blandizzi; Alessandro Mugelli; Mario Del Tacca
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

Review 7.  Statins in High Cardiovascular Risk Patients: Do Comorbidities and Characteristics Matter?

Authors:  Enrica Rossini; Federico Biscetti; Maria Margherita Rando; Elisabetta Nardella; Andrea Leonardo Cecchini; Maria Anna Nicolazzi; Marcello Covino; Antonio Gasbarrini; Massimo Massetti; Andrea Flex
Journal:  Int J Mol Sci       Date:  2022-08-18       Impact factor: 6.208

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.